New drug targets for Alzheimer’s identified from cerebrospinal fluid (Links to an external site)
Study pegs certain cellular activities to driving Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and progression.
A Country Doctor, But Oh So Much More: Francisco Lopera, 73 (Links to an external site)
The DIAN and DIAN-TU are deeply saddened by the recent death of our beloved colleague, Dr. Francisco Lopera, Principal Investigator at our site in Colombia (Grupo Neurociencias de Antioquia – GNA). Alzforum offers this remembrance, highlighting the impact of Dr. Lopera’s work on the AD field.
First Success Stories From Alzheimer’s Secondary Prevention Trial (Links to an external site)
As discussed at the Alzheimer’s Association International Conference in Philadelphia, nearly two dozen mutation carriers who took gantenerumab for eight years had half the risk of developing symptoms as did untreated controls.
Living Among Us: People Whose Alzheimer’s Is Already Being Prevented (Links to an external site)
Many researchers think the full promise of plaque removal lies in prevention. If plaques were abolished before they could kick off downstream pathologies such as tangles, would the disease be stopped in its tracks?
The Knight Family DIAN-TU-003 Amyloid Removal Trial
DIAN-TU is launching the DIAN-TU-003 Amyloid Removal Trial (ART) to enable continued treatment for the DIAN-TU-001 Gantenerumab Open Label Extension (OLE) participants and address questions regarding the effects of removing amyloid plaques to normal levels on cognitive symptoms, clinical progression and disease processes.
The Knight Family DIAN-TU Primary Prevention Trial
We are now pleased to announce plans to re-launch the DIAN-TU-002 Primary Prevention Trial with remternetug in collaboration with Eli Lilly and Company (Lilly).
The New Age of Alzheimer’s (Links to an external site)
The soaring burden of dementia threatens global health. Science is paving new paths to solutions.
Moment of promise (Links to an external site)
WashU School of Medicine recently dedicated the new 609,000-square-foot Jeffrey T. Fort Neuroscience Research Building, which houses some 120 research teams — one of the highest concentrations of neuroscientists in the world.
Alzheimer’s Association and GHR Foundation Commit $4 Million to Extend Prevention Trial in Rare Alzheimer’s (Links to an external site)
The Knight Family DIAN-TU Amyloid Removal Trial
Update to the 18 August 2023 announcement by the Knight Family DIAN-TU regarding the DIAN-TU-001 Open Label Extension (OLE) Study
Update on the DIAN-TU-001 Gantenerumab Open Label Extension
This announcement is regarding the Knight Family DIAN-TU Open Label Extension (OLE) Study with gantenerumab (made by Roche and Genentech)
Podcast: Newly approved drug may slow progression of Alzheimer’s (Links to an external site)
Lilly drug slows Alzheimer’s by 35%, bolstering treatment approach (Links to an external site)
Update on the DIAN-TU-001 Open Label Extension with Gantenerumab (Roche/Genentech)
Questions and concerns from sites and participants regarding the status of the DIAN-TU-001 gantenerumab open label extension (OLE) study and next steps in the study.
Conquering Alzheimer’s: a look at the therapies of the future (Links to an external site)
Seeking Alzheimer’s clues from few who escape genetic fate (Links to an external site)
Lifetime Achievement Award (Links to an external site)
Focused ultrasound technique leads to release of neurodegenerative disorders biomarkers (Links to an external site)
FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE (Links to an external site)
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
Response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for the treatment of symptomatic Alzheimer’s disease (AD)
Update on the DIAN-TU-002 Primary Prevention Trial
Update to the 15 November 2022 announcement by the Knight Family Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) regarding the DIAN-TU-002 Primary Prevention Trial with Gantenerumab.
WashU, Eisai form drug discovery collaboration (Links to an external site)
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website. Roche, known as Genentech in the United States, and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University in St. Louis have been evaluating gantenerumab in […]
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease (Links to an external site)
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
Response to the 14-November-2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE (Links to an external site)
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
Response to the 28 September 2022 announcement found on Eisai’s website.
Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease (Links to an external site)
Could drugs prevent Alzheimer’s? These trials aim to find out (Links to an external site)
Blood test for Alzheimer’s highly accurate in large, international study (Links to an external site)
